Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Cerilliant
Fish and Richardson
Baxter
US Department of Justice
Deloitte
Boehringer Ingelheim
Dow
Medtronic
Federal Trade Commission

Generated: February 23, 2018

DrugPatentWatch Database Preview

RASUVO Drug Profile

« Back to Dashboard

When do Rasuvo patents expire, and what generic alternatives are available?

Rasuvo is a drug marketed by Medac Pharma Inc and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-seven patent family members in nineteen countries.

The generic ingredient in RASUVO is methotrexate. There are twenty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methotrexate profile page.

US Patents and Regulatory Information for RASUVO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-001 Jul 10, 2014 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-007 Jul 10, 2014 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-004 Jul 10, 2014 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-008 Jul 10, 2014 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-002 Jul 10, 2014 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-003 Jul 10, 2014 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-006 Jul 10, 2014 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-005 Jul 10, 2014 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-010 Jul 10, 2014 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-009 Jul 10, 2014 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for RASUVO

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
McKinsey
UBS
Federal Trade Commission
McKesson
Mallinckrodt
Argus Health
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot